At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
bevacizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Bevacizumab and Erlotinib in Elderly Patients With Advanced Non-Small Lung Cancer
In Brief
A Phase 2 clinical trial evaluating bevacizumab and Erlotinib for Carcinoma, Non-Small-Cell Lung. Completed, enrolled 32 participants across 7 sites.
Detailed Summary
This study will evaluate the combination of bevacizumab and erlotinib in elderly patients with advanced non-small cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non-Small-Cell Lung
CountriesUnited States
CollaboratorsGenentech, Inc., OSI Pharmaceuticals
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
First PostedNov 2007
Primary CompletionJan 2011
Study CompletionJun 2011
TodayJul 2026
First PostedNov 6, 2007
Enrollment StartJul 5, 2007
Primary CompletionJan 12, 2011
Study CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 18.7 years ago
Interventions
bevacizumabdrug
Erlotinibdrug